Abbott: 3 Key Takeaways for Long-Term Investors
Pulsed field ablation and expanded cancer screening tools position the core business for accelerated growth beyond historical rates.
On October 21, 2026, Abbott announced plans to spin off its nutrition business into an independent public company during its third quarter earnings call. This move aims to focus on higher-margin medical technologies and diagnostics, resulting in a faster-growing enterprise. The three key takeaways from the call are:
1. Creating a pure-play consumer health business by separating adult and pediatric nutrition will shift the remaining portfolio toward faster-growing medical devices and diagnostics. This structural change is expected to boost sales growth rates and expand overall profit margins.
2. The nutrition market has become increasingly shaped by changing consumer preferences, wellness trends, and retail execution, transforming from a healthcare market dominated by healthcare professionals. This market evolution, while not inherently positive or negative, has fundamentally altered the operating environment.
3. Expanding precision oncology and colorectal screening tools provides the diagnostic segment with a reliable growth engine. Integrating advanced screening platforms increases test volume across clinical healthcare networks, with cancer diagnostics driving sales growth in 14% through products like Cologuard and precision oncology, as well as international businesses. The launch of Abbott's first blood-based colorectal cancer screening test in September further strengthens this growth driver.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.